Health Catalyst (HCAT) Exceeds Expectations in Q3 Earnings and Revenue
Earnings Performance: Health Catalyst (HCAT) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05, although down from $0.07 a year ago. The company also surpassed revenue expectations with $76.32 million, slightly below last year's $76.35 million.
Stock Outlook: Despite the earnings beat, Health Catalyst shares have declined about 60% this year, contrasting with the S&P 500's 14.4% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Future Earnings Estimates: The consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $74.59 million, with a fiscal year estimate of $0.19 on $309.8 million in revenues. The outlook for the industry may significantly influence the stock's performance.
Industry Context: Health Catalyst operates within the Zacks Medical Info Systems industry, which ranks in the top 27% of over 250 Zacks industries. Another industry player, Veeva Systems, is set to report its earnings soon, with expectations of a year-over-year earnings increase.
Trade with 70% Backtested Accuracy
Analyst Views on HCAT
About HCAT
About the author
Health Catalyst Appoints First Light CEO Matt Arens to Board, Holding 19% Stake
- New Board Member: Health Catalyst announced the appointment of Matt Arens, CEO of First Light, to its board effective December 1, 2025, with First Light being the largest shareholder holding approximately 19% of shares, which is expected to bring valuable capital market experience to enhance shareholder value.
- Shareholder Value Creation: With over 30 years in the investment field, Arens focuses on identifying growth opportunities in healthcare companies, and his addition is anticipated to sharpen Health Catalyst's strategic focus in healthcare data analytics, enabling measurable healthcare improvements.
- Leadership Transition: Current board member Matthew Kolb will not seek re-election, which is expected to create more room for new members, enhancing the board's diversity and expertise, thereby furthering the company's strategic objectives.
- Market Potential: Arens stated that the market is not fully recognizing the embedded value within Health Catalyst, and with a low EBITDA multiple and high free cash flow potential, significant appreciation in the company's shares is expected, boosting investor confidence.
Health Catalyst Appoints First Light Founder Matt Arens to Board, Holding 19% Shares
- New Board Member: Health Catalyst announced the appointment of Matt Arens, founder of First Light, to its board, with Arens and his firm holding approximately 13.9 million shares, or about 19% of the company, which is expected to bring deep capital market experience to the company.
- Shareholder Value Enhancement: Arens's investment experience in the healthcare sector will assist Health Catalyst in identifying and creating significant shareholder value, advancing the company's strategic goals in data-driven healthcare improvement.
- Leadership Transition: Current director Matthew Kolb will not stand for re-election, which is expected to provide greater development space for new members and further drive the board's strategic direction.
- Market Potential: Arens noted that the market has not fully recognized the embedded value within Health Catalyst, and combined with a low EBITDA multiple and high free cash flow generation potential, indicates significant appreciation opportunities for the company's shares.
Health Catalyst to Attend Upcoming Investor Conferences
Upcoming Investor Conferences: Health Catalyst, Inc. will participate in several investor conferences, including the Stephens Annual Investment Conference on November 19, 2025, and the Canaccord Genuity MedTech Forum on November 20, 2025, featuring key executives in discussions and meetings.
Company Overview: Health Catalyst is a leading provider of data and analytics technology for healthcare organizations, with over 1,100 clients relying on its solutions to drive clinical, financial, and operational improvements.
Technology and Services: The company offers a cloud-based technology ecosystem, Health Catalyst Ignite™, which utilizes AI-enabled data analytics to transform complex healthcare information into actionable insights.
Proven Impact: Health Catalyst has a multi-decade mission focused on delivering measurable results, claiming to have generated billions of dollars in improvements across healthcare systems worldwide.
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.
KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.
Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.
Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.
Health Catalyst (HCAT) Q3 Earnings Review: Analyzing Key Metrics Against Expectations
Health Catalyst Financial Performance: For Q3 2025, Health Catalyst reported revenue of $76.32 million, unchanged from the previous year, with an EPS of $0.06, down from $0.07 a year ago.
Earnings Surprises: The company's revenue exceeded the Zacks Consensus Estimate by 1.66%, and it delivered a 20% EPS surprise compared to the consensus estimate of $0.05.
Investor Insights: Key metrics beyond headline numbers are crucial for understanding a company's performance and guiding investors' decisions regarding stock price projections.
Stock Recommendations: Zacks Investment Research highlighted five stocks with potential for significant growth, emphasizing opportunities in lesser-known stocks that have previously shown substantial returns.
Health Catalyst (HCAT) Exceeds Expectations in Q3 Earnings and Revenue
Earnings Performance: Health Catalyst (HCAT) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05, although down from $0.07 a year ago. The company also surpassed revenue expectations with $76.32 million, slightly below last year's $76.35 million.
Stock Outlook: Despite the earnings beat, Health Catalyst shares have declined about 60% this year, contrasting with the S&P 500's 14.4% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Future Earnings Estimates: The consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $74.59 million, with a fiscal year estimate of $0.19 on $309.8 million in revenues. The outlook for the industry may significantly influence the stock's performance.
Industry Context: Health Catalyst operates within the Zacks Medical Info Systems industry, which ranks in the top 27% of over 250 Zacks industries. Another industry player, Veeva Systems, is set to report its earnings soon, with expectations of a year-over-year earnings increase.
Health Catalyst Appoints First Light CEO Matt Arens to Board, Holding 19% Stake
- New Board Member: Health Catalyst announced the appointment of Matt Arens, CEO of First Light, to its board effective December 1, 2025, with First Light being the largest shareholder holding approximately 19% of shares, which is expected to bring valuable capital market experience to enhance shareholder value.
- Shareholder Value Creation: With over 30 years in the investment field, Arens focuses on identifying growth opportunities in healthcare companies, and his addition is anticipated to sharpen Health Catalyst's strategic focus in healthcare data analytics, enabling measurable healthcare improvements.
- Leadership Transition: Current board member Matthew Kolb will not seek re-election, which is expected to create more room for new members, enhancing the board's diversity and expertise, thereby furthering the company's strategic objectives.
- Market Potential: Arens stated that the market is not fully recognizing the embedded value within Health Catalyst, and with a low EBITDA multiple and high free cash flow potential, significant appreciation in the company's shares is expected, boosting investor confidence.
Health Catalyst Appoints First Light Founder Matt Arens to Board, Holding 19% Shares
- New Board Member: Health Catalyst announced the appointment of Matt Arens, founder of First Light, to its board, with Arens and his firm holding approximately 13.9 million shares, or about 19% of the company, which is expected to bring deep capital market experience to the company.
- Shareholder Value Enhancement: Arens's investment experience in the healthcare sector will assist Health Catalyst in identifying and creating significant shareholder value, advancing the company's strategic goals in data-driven healthcare improvement.
- Leadership Transition: Current director Matthew Kolb will not stand for re-election, which is expected to provide greater development space for new members and further drive the board's strategic direction.
- Market Potential: Arens noted that the market has not fully recognized the embedded value within Health Catalyst, and combined with a low EBITDA multiple and high free cash flow generation potential, indicates significant appreciation opportunities for the company's shares.
Health Catalyst to Attend Upcoming Investor Conferences
Upcoming Investor Conferences: Health Catalyst, Inc. will participate in several investor conferences, including the Stephens Annual Investment Conference on November 19, 2025, and the Canaccord Genuity MedTech Forum on November 20, 2025, featuring key executives in discussions and meetings.
Company Overview: Health Catalyst is a leading provider of data and analytics technology for healthcare organizations, with over 1,100 clients relying on its solutions to drive clinical, financial, and operational improvements.
Technology and Services: The company offers a cloud-based technology ecosystem, Health Catalyst Ignite™, which utilizes AI-enabled data analytics to transform complex healthcare information into actionable insights.
Proven Impact: Health Catalyst has a multi-decade mission focused on delivering measurable results, claiming to have generated billions of dollars in improvements across healthcare systems worldwide.
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.
KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.
Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.
Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.
Health Catalyst (HCAT) Q3 Earnings Review: Analyzing Key Metrics Against Expectations
Health Catalyst Financial Performance: For Q3 2025, Health Catalyst reported revenue of $76.32 million, unchanged from the previous year, with an EPS of $0.06, down from $0.07 a year ago.
Earnings Surprises: The company's revenue exceeded the Zacks Consensus Estimate by 1.66%, and it delivered a 20% EPS surprise compared to the consensus estimate of $0.05.
Investor Insights: Key metrics beyond headline numbers are crucial for understanding a company's performance and guiding investors' decisions regarding stock price projections.
Stock Recommendations: Zacks Investment Research highlighted five stocks with potential for significant growth, emphasizing opportunities in lesser-known stocks that have previously shown substantial returns.
Health Catalyst (HCAT) Exceeds Expectations in Q3 Earnings and Revenue
Earnings Performance: Health Catalyst (HCAT) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05, although down from $0.07 a year ago. The company also surpassed revenue expectations with $76.32 million, slightly below last year's $76.35 million.
Stock Outlook: Despite the earnings beat, Health Catalyst shares have declined about 60% this year, contrasting with the S&P 500's 14.4% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Future Earnings Estimates: The consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $74.59 million, with a fiscal year estimate of $0.19 on $309.8 million in revenues. The outlook for the industry may significantly influence the stock's performance.
Industry Context: Health Catalyst operates within the Zacks Medical Info Systems industry, which ranks in the top 27% of over 250 Zacks industries. Another industry player, Veeva Systems, is set to report its earnings soon, with expectations of a year-over-year earnings increase.
